ALK5 and ALK1 play antagonistic roles in transforming growth factor β-induced podosome formation in aortic endothelial cells

Molecular and Cellular Biology

Volumn 34, Issue 24, 2014, Pages 4389-4403

  Curado, Filipa ^a   Spuul, Pirjo ^a   Egaña, Isabel ^a   Rottiers, Patricia ^a   Daubon, Thomas ^a   Veillat, Véronique ^a   Duhamel, Paul ^a   Leclercq, Anne ^a   Gontier, Etienne ^a   Génot, Elisabeth ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN 9; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; ACTIVIN RECEPTOR; PROTEIN SERINE THREONINE KINASE; RECEPTOR REGULATED SMAD PROTEIN; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; AORTIC ENDOTHELIAL CELL; ARTICLE; CELL TYPE; CONTROLLED STUDY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; IN VITRO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PODOSOME; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; ACTIN FILAMENT; ANIMAL; AORTA; BOVINE; C57BL MOUSE; CYTOLOGY; ENDOTHELIUM CELL; METABOLISM; TRANSGENIC MOUSE;

BOVINAE;

ACTIN CYTOSKELETON; ACTIVIN RECEPTORS; ANIMALS; AORTA; CATTLE; ENDOTHELIAL CELLS; GROWTH DIFFERENTIATION FACTOR 2; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS, RECEPTOR-REGULATED; TRANSFORMING GROWTH FACTOR BETA;

EID: 84918835995     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01026-14     Document Type: Article

References (56)

1. Linder S, Wiesner C, Himmel M. 2011. Degrading devices: invadosomes in proteolytic cell invasion. Annu. Rev. Cell Dev. Biol. 27:185-211. http://dx.doi.org/10.1146/annurev-cellbio-092910-154216.
2. Varon C, Tatin F, Moreau V, Van Obberghen-Schilling E, Fernandez-Sauze S, Reuzeau E, Kramer I, Genot E. 2006. Transforming growth factor beta induces rosettes of podosomes in primary aortic endothelial cells. Mol. Cell. Biol. 26:3582-3594. http://dx.doi.org/10.1128/MCB.26.9.3582-3594.2006.
3. Rottiers P, Saltel F, Daubon T, Chaigne-Delalande B, Tridon V, Billottet C, Reuzeau E, Genot E. 2009. TGFbeta-induced endothelial podosomes mediate basement membrane collagen degradation in arterial vessels. J. Cell Sci. 122:4311-4318. http://dx.doi.org/10.1242/jcs.057448.
4. Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-584. http://dx.doi.org/10.1038/nature02006.
5. ten Dijke P, Hill CS. 2004. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 29:265-273. http://dx.doi.org/10.1016/j.tibs.2004.03.008.
6. Moustakas A, Heldin CH. 2005. Non-Smad TGF-beta signals. J. Cell Sci. 118:3573-3584. http://dx.doi.org/10.1242/jcs.02554.
7. Shi Y, Massague J. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700. http://dx.doi.org/10.1016/S0092-8674(03)00432-X.
8. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell 12:817-828. http://dx.doi.org/10.1016/S1097-2765(03)00386-1.
9. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. 2002. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 21:1743-1753. http://dx.doi.org/10.1093/emboj/21.7.1743.
10. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. 2000. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 97:2626-2631. http://dx.doi.org/10.1073/pnas.97.6.2626.
11. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. 2005. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factorbeta receptor complex. J. Cell. Physiol. 204:574-584. http://dx.doi.org/10.1002/jcp.20311.
12. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P. 2004. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 23:4018-4028. http://dx.doi.org/10.1038/sj.emboj.7600386.
13. David L, Mallet C, Keramidas M, Lamande N, Gasc JM, Dupuis-Girod S, Plauchu H, Feige JJ, Bailly S. 2008. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res. 102:914-922. http://dx.doi.org/10.1161/CIRCRESAHA.107.165530.
14. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. 2007. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109:1953-1961. http://dx.doi.org/10.1182/blood-2006-07-034124.
15. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Lowik CW, ten Dijke P. 2007. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGFstimulated angiogenesis. J. Cell Sci. 120:964-972. http://dx.doi.org/10.1242/jcs.002949.
16. Wang X, Abraham S, McKenzie JA, Jeffs N, Swire M, Tripathi VB, Luhmann UF, Lange CA, Zhai Z, Arthur HM, Bainbridge JW, Moss SE, Greenwood J. 2013. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 499:306-311. http://dx.doi.org/10.1038/nature12345.
17. Peery WH. 1987. Clinical spectrum of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Am. J. Med. 82:989-997. http://dx.doi.org/10.1016/0002-9343(87)90162-8.
18. Hume AN, John A, Akawi NA, Al-Awadhi AM, Al-Suwaidi SS, Al-Gazali L, Ali BR. 2013. Retention in the endoplasmic reticulum is the underlying mechanism of some hereditary haemorrhagic telangiectasia type 2 ALK1 missense mutations. Mol. Cell. Biochem. 373:247-257. http://dx.doi.org/10.1007/s11010-012-1496-3.
19. Ricard N, Ciais D, Levet S, Subileau M, Mallet C, Zimmers TA, Lee SJ, Bidart M, Feige JJ, Bailly S. 2012. BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood 119:6162-6171. http://dx.doi.org/10.1182/blood-2012-01-407593.
20. Park SO, Lee YJ, Seki T, Hong KH, Fliess N, Jiang Z, Park A, Wu X, Kaartinen V, Roman BL, Oh SP. 2008. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 111:633-642. http://dx.doi.org/10.1182/blood-2007-08-107359.
21. Park SO, Wankhede M, Lee YJ, Choi EJ, Fliess N, Choe SW, Oh SH, Walter G, Raizada MK, Sorg BS, Oh SP. 2009. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 119:3487-3496. http://dx.doi.org/10.1172/JCI39482.
22. Urness LD, Sorensen LK, Li DY. 2000. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat. Genet. 26:328-331. http://dx.doi.org/10.1038/81634.
23. Fernandez-Lopez A, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Hebbel RP, Nguyen J, Bernabeu C, Botella LM. 2005. Blood outgrowth endothelial cells from hereditary haemorrhagic telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc. Res. 68:235-248. http://dx.doi.org/10.1016/j.cardiores.2005.06.009.
24. Shao ES, Lin L, Yao Y, Bostrom KI. 2009. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114:2197-2206. http://dx.doi.org/10.1182/blood-2009-01-199166.
25. Castañares C, Redondo-Horcajo M, Magan-Marchal N, ten Dijke P, Lamas S, Rodriguez-Pascual F. 2007. Signaling by ALK5 mediates TGFbeta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J. Cell Sci. 120:1256-1266. http://dx.doi.org/10.1242/jcs.03419.
26. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, Lopez-Novoa JM, Attisano L, Bernabeu C. 2007. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J. Cell. Physiol. 210:456-468. http://dx.doi.org/10.1002/jcp.20878.
27. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9:671-675. http://dx.doi.org/10.1038/nmeth.2089.
28. Star GP, Giovinazzo M, Langleben D. 2010. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: a potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension. Microvasc. Res. 80:349-354. http://dx.doi.org/10.1016/j.mvr.2010.05.010.
29. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, Seehra J, Heldin CH, ten Dijke P, Pietras K. 2010. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J. Exp. Med. 207:85-100. http://dx.doi.org/10.1084/jem.20091309.
30. Attisano L, Wrana JL. 2002. Signal transduction by the TGF-beta superfamily. Science 296:1646-1647. http://dx.doi.org/10.1126/science.1071809.
31. Vogt J, Traynor R, Sapkota GP. 2011. The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell. Signal. 23:1831-1842. http://dx.doi.org/10.1016/j.cellsig.2011.06.019.
32. Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH, ten Dijke P. 2003. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J. Biol. Chem. 278:3751-3761. http://dx.doi.org/10.1074/jbc.M208258200.
33. Donners MM, Wolfs IM, Stoger LJ, van der Vorst EP, Pottgens CC, Heymans S, Schroen B, Gijbels MJ, de Winther MP. 2012. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One 7:e35877. http://dx.doi.org/10.1371/journal.pone.0035877.
34. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. 2009. miR-155 gene: a typical multifunctional microRNA. Biochim. Biophys. Acta 1792:497-505. http://dx.doi.org/10.1016/j.bbadis.2009.02.013.
35. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. 2010. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc. Natl. Acad. Sci. U. S. A. 107:3111-3116. http://dx.doi.org/10.1073/pnas.0910667107.
36. Massagué J, Chen YG. 2000. Controlling TGF-beta signaling. Genes Dev. 14:627-644. http://dx.doi.org/10.1101/gad.14.6.627.
37. Suwanabol PA, Kent KC, Liu B. 2011. TGF-beta and restenosis revisited: a Smad link. J. Surg. Res. 167:287-297. http://dx.doi.org/10.1016/j.jss.2010.12.020.
38. Xu C, Lee S, Shu C, Masuda H, Zarins CK. 2002. Expression of TGFbeta1 and beta3 but not apoptosis factors relates to flow-induced aortic enlargement. BMC Cardiovasc. Disord. 2:11. http://dx.doi.org/10.1186/1471-2261-2-11.
39. Goumans MJ, Lebrin F, Valdimarsdottir G. 2003. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc. Med. 13:301-307. http://dx.doi.org/10.1016/S1050-1738(03)00142-7.
40. Daly AC, Randall RA, Hill CS. 2008. Transforming growth factor betainduced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol. Cell. Biol. 28:6889-6902. http://dx.doi.org/10.1128/MCB.01192-08.
41. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK. 1996. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 86:435-444. http://dx.doi.org/10.1016/S0092-8674(00)80116-6.
42. Lee NY, Haney JC, Sogani J, Blobe GC. 2009. Casein kinase 2beta as a novel enhancer of activin-like receptor-1 signaling. FASEB J. 23:3712-3721. http://dx.doi.org/10.1096/fj.09-131607.
43. Mo J, Fang SJ, Chen W, Blobe GC. 2002. Regulation of ALK-1 signaling by the nuclear receptor LXRbeta. J. Biol. Chem. 277:50788-50794. http://dx.doi.org/10.1074/jbc.M210376200.
44. Guttmacher AE, Marchuk DA, White RI, Jr. 1995. Hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 333:918-924. http://dx.doi.org/10.1056/NEJM199510053331407.
45. Hashimoto K, Pritzker MS. 1972. Hereditary hemorrhagic telangiectasia. An electron microscopic study. Oral Surg. Oral Med. Oral Pathol. 34:751-768. http://dx.doi.org/10.1016/0030-4220(72)90293-9.
46. Quintavalle M, Elia L, Condorelli G, Courtneidge SA. 2010. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J. Cell Biol. 189:13-22. http://dx.doi.org/10.1083/jcb.200912096.
47. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G. 2009. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 16:1590-1598. http://dx.doi.org/10.1038/cdd.2009.153.
48. Hill CS. 2009. Nucleocytoplasmic shuttling of Smad proteins. Cell Res. 19:36-46. http://dx.doi.org/10.1038/cr.2008.325.
49. Bijkerk R, de Bruin RG, van Solingen C, Duijs JM, Kobayashi K, van der Veer EP, ten Dijke P, Rabelink TJ, Goumans MJ, van Zonneveld AJ. 2012. MicroRNA-155 functions as a negative regulator of RhoA signaling in TGF-beta-induced endothelial to mesenchymal transition. Microrna 1:2-10. http://dx.doi.org/10.2174/2211536611201010002.
50. Moreau V, Tatin F, Varon C, Genot E. 2003. Actin can reorganize into podosomes in aortic endothelial cells, a process controlled by Cdc42 and RhoA. Mol. Cell. Biol. 23:6809-6822. http://dx.doi.org/10.1128/MCB.23.19.6809-6822.2003.
51. Roberts AB, Russo A, Felici A, Flanders KC. 2003. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann. N. Y. Acad. Sci. 995:1-10. http://dx.doi.org/10.1111/j.1749-6632.2003.tb03205.x.
52. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF. 1999. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol. Cell. Biol. 19:2495-2504.
53. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. 1999. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J. Biol. Chem. 274:703-709.
54. Billottet C, Rottiers P, Tatin F, Varon C, Reuzeau E, Maitre JL, Saltel F, Moreau V, Genot E. 2008. Regulatory signals for endothelial podosome formation. Eur. J. Cell Biol. 87:543-554. http://dx.doi.org/10.1016/j.ejcb.2008.02.006.
55. Daubon T, Buccione R, Genot E. 2011. The Aarskog-Scott syndrome protein Fgd1 regulates podosome formation and extracellular matrix remodeling in transforming growth factor beta-stimulated aortic endothelial cells. Mol. Cell. Biol. 31:4430-4441. http://dx.doi.org/10.1128/MCB.05474-11.
56. Urness LD, Sorenesen LK, Li DY. 2000. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat. Genet. 26:328-331. http://dx.doi.org/10.1038/8163.4.